Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery

Exclusion Criteria

• •Known or suspected hereditary or acquired bleeding or coagulation disorders in the participant or his or her first-degree relative
• •Known or suspected history of heparin-induced thrombocytopenia
• •Known coagulopathy
• •Active bleeding or at high risk for bleeding
• •Brain, spinal, ophthalmologic, or major surgery or trauma within the past 90 days
• •Active hepatobiliary disease
• •Alcohol and/or substance abuse within the past year
• •Any condition for which, in the opinion of the investigator, surgery or administration of an anticoagulant was contraindicated
• •Two consecutive blood pressure readings within 15 to 30 minutes with supine systolic blood pressure \>180 mm Hg or supine diastolic blood pressure \>105 mm Hg
• •Clinically significant laboratory abnormalities at the enrollment visit:
• •* Hemoglobin \<10 g/dL
• •* Platelet count \<100,000/mm\^3
• •* Creatinine clearance \<30 mL/min, as estimated by the method of Cockcroft and Gault
• •* Alanine aminotransferase or aspartate aminotransferase level \>2\*upper limit of normal (ULN) or a total bilirubin ≥1.5\*ULN (unless an alternative causative factor such as Gilbert's syndrome was identified)